Empirical Relative Biological Effectiveness (RBE) for Mandible Osteoradionecrosis (ORN) in Head and Neck Cancer Patients Treated With Pencil-Beam-Scanning Proton Therapy (PBSPT): A Retrospective, Case-Matched Cohort Study

Purpose To retrospectively investigate empirical relative biological effectiveness (RBE) for mandible osteoradionecrosis (ORN) in head and neck (H&N) cancer patients treated with pencil-beam-scanning proton therapy (PBSPT). Methods We included 1,266 H&N cancer patients, of which, 931 patients were treated with volumetric-modulated arc therapy (VMAT) and 335 were treated with PBSPT. Among them, 26 VMAT and 9 PBSPT patients experienced mandible ORN (ORN group), while all others were included in the control group. To minimize the impact of the possible imbalance in clinical factors between VMAT and PBSPT patients in the dosimetric comparison between these two modalities and the resulting RBE quantification, we formed a 1:1 case-matched patient cohort (335 VMAT patients and 335 PBSPT patients including both the ORN and control groups) using the greedy nearest neighbor matching of propensity scores. Mandible dosimetric metrics were extracted from the case-matched patient cohort and statistically tested to evaluate the association with mandibular ORN to derive dose volume constraints (DVCs) for VMAT and PBSPT, respectively. We sought the equivalent constraint doses for VMAT so that the critical volumes of VMAT were equal to those of PBSPT at different physical doses. Empirical RBEs of PBSPT for ORN were obtained by calculating the ratio between the derived equivalent constraint doses and physical doses of PBSPT. Bootstrapping was further used to get the confidence intervals. Results Clinical variables of age, gender, tumor stage, prescription dose, chemotherapy, hypertension or diabetes, dental extraction, smoking history, or current smoker were not statistically related to the incidence of ORN in the overall patient cohort. Smoking history was found to be significantly associated with the ORN incidence in PBSPT patients only. V40Gy[RBE], V50Gy[RBE], and V60Gy[RBE] were statistically different (p<0.05) between the ORN and control group for VMAT and PBSPT. Empirical RBEs of 1.58(95%CI: 1.34-1.64), 1.34(95%CI: 1.23-1.40), and 1.24(95%: 1.15-1.26) were obtained for proton dose at 40 Gy[RBE=1.1], 50 Gy[RBE=1.1] and 60 Gy[RBE=1.1], respectively. Conclusions Our study suggested that RBEs were larger than 1.1 at moderate doses (between 40 and 60 Gy[RBE=1.1]) with high LET for mandible ORN. RBEs are underestimated in current clinical practice in PBSPT. The derived DVCs can be used for PBSPT plan evaluation and optimization to minimize the incidence rate of mandible ORN.

[1]  M. Bues,et al.  Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity-Modulated Proton Therapy (IMPT). , 2021, International journal of radiation oncology, biology, physics.

[2]  C. Fuller,et al.  Normal Tissue Complication Probability (NTCP) Prediction Model for Osteoradionecrosis of the Mandible in Patients With Head and Neck Cancer After Radiation Therapy: Large-Scale Observational Cohort , 2021, medRxiv.

[3]  Jun Ma,et al.  Brain-specific RBE of Protons Based on Long-term Outcome of Patients with Nasopharyngeal Carcinoma. , 2021, International journal of radiation oncology, biology, physics.

[4]  V. Takiar,et al.  Osteoradionecrosis: Exposing the Evidence Not the Bone. , 2021, International journal of radiation oncology, biology, physics.

[5]  K. Herfarth,et al.  Late contrast enhancing brain lesions in proton treated low-grade glioma patients: clinical evidence for increased periventricular sensitivity and variable RBE. , 2020, International journal of radiation oncology, biology, physics.

[6]  Sheng Huang,et al.  Technical Note: Integrating an open source Monte Carlo code "MCsquare" for clinical use in intensity-modulated proton therapy. , 2020, Medical physics.

[7]  S. Schild,et al.  Robust Optimization for Intensity-Modulated Proton Therapy to Redistribute High Linear Energy Transfer (LET) from Nearby Critical Organs to Tumors in Head and Neck Cancer. , 2020, International journal of radiation oncology, biology, physics.

[8]  S. Schild,et al.  Hybrid 3D analytical Linear Energy Transfer calculation algorithm based on pre-calculated data from Monte Carlo simulations. , 2019, Medical physics.

[9]  C. Hansen,et al.  Osteoradionecrosis of the mandible after radiotherapy for head and neck cancer: risk factors and dose-volume correlations , 2019, Acta oncologica.

[10]  T. Sio,et al.  Dosimetric comparison of distal esophageal carcinoma plans for patients treated with small‐spot intensity‐modulated proton versus volumetric‐modulated arc therapies , 2019, Journal of applied clinical medical physics.

[11]  T. Sio,et al.  Small‐spot intensity‐modulated proton therapy and volumetric‐modulated arc therapies for patients with locally advanced non‐small‐cell lung cancer: A dosimetric comparative study , 2018, Journal of applied clinical medical physics.

[12]  Wei Liu,et al.  Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. , 2018, International journal of radiation oncology, biology, physics.

[13]  Wei Liu,et al.  Molecular mechanism of bystander effects and related abscopal/cohort effects in cancer therapy , 2018, Oncotarget.

[14]  C. Mayo,et al.  Data collection of patient outcomes: one institution’s experience , 2018, Journal of radiation research.

[15]  M. Ehrenfeld,et al.  Osteoradionecrosis of the jaws: definition, epidemiology, staging and clinical and radiological findings. A concise review. , 2018, International dental journal.

[16]  Radhe Mohan,et al.  Linear energy transfer incorporated intensity modulated proton therapy optimization , 2017, Physics in medicine and biology.

[17]  Wei Liu,et al.  Robust intensity‐modulated proton therapy to reduce high linear energy transfer in organs at risk , 2017, Medical physics.

[18]  B. O'Sullivan,et al.  Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity‐modulated radiotherapy , 2017, Cancer.

[19]  Mona Kamal,et al.  Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  A. Garden,et al.  Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  Harald Paganetti,et al.  Reoptimization of Intensity Modulated Proton Therapy Plans Based on Linear Energy Transfer. , 2016, International journal of radiation oncology, biology, physics.

[22]  Wei Liu,et al.  Robustness quantification methods comparison in volumetric modulated arc therapy to treat head and neck cancer. , 2016, Practical radiation oncology.

[23]  Wei Liu,et al.  Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. , 2016, International journal of radiation oncology, biology, physics.

[24]  I. Das,et al.  Dose perturbation effect of metallic spinal implants in proton beam therapy , 2015, Journal of applied clinical medical physics.

[25]  Wei Liu,et al.  Dosimetric benefits of robust treatment planning for intensity modulated proton therapy for base-of-skull cancers. , 2014, Practical radiation oncology.

[26]  Harald Paganetti,et al.  Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer , 2014, Physics in medicine and biology.

[27]  Peter C Austin,et al.  A comparison of 12 algorithms for matching on the propensity score , 2013, Statistics in medicine.

[28]  A. Garden,et al.  Osteoradionecrosis and radiation dose to the mandible in patients with oropharyngeal cancer. , 2013, International journal of radiation oncology, biology, physics.

[29]  R. Mohan,et al.  Robust optimization of intensity modulated proton therapy. , 2012, Medical physics.

[30]  Radhe Mohan,et al.  Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. , 2011, International journal of radiation oncology, biology, physics.

[31]  Anders Forsgren,et al.  Minimax optimization for handling range and setup uncertainties in proton therapy. , 2011, Medical physics.

[32]  A. Garden,et al.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  U Oelfke,et al.  Worst case optimization: a method to account for uncertainties in the optimization of intensity modulated proton therapy , 2008, Physics in medicine and biology.

[34]  A J Lomax,et al.  Intensity modulated proton therapy and its sensitivity to treatment uncertainties 2: the potential effects of inter-fraction and inter-field motions , 2008, Physics in medicine and biology.

[35]  A. Lomax,et al.  Intensity modulated proton therapy and its sensitivity to treatment uncertainties 1: the potential effects of calculational uncertainties , 2008, Physics in medicine and biology.

[36]  J. Buatti,et al.  Radiation doses to structures within and adjacent to the larynx are correlated with long-term diet- and speech-related quality of life. , 2005, International journal of radiation oncology, biology, physics.

[37]  K. Vineberg,et al.  Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? , 2004, International journal of radiation oncology, biology, physics.

[38]  Harald Paganetti,et al.  Relative biological effectiveness (RBE) values for proton beam therapy. , 2002, International journal of radiation oncology, biology, physics.

[39]  Wei Liu,et al.  Robust treatment planning with conditional value at risk chance constraints in intensity‐modulated proton therapy , 2017, Medical physics.